Competitive Technologies Adds New Technologies to Portfolio.

FAIRFIELD, Conn. -- Competitive Technologies, Inc. (AMEX: CTT) today announced that it has selected several new and promising technologies for its portfolio. The first is a robust intellectual property in the area of metallurgy. This patent pending process greatly increases the efficiency in the forming of thin-walled, hollow structures, such as those used to form certain high value fuel tanks used in shipping, aerospace and energy applications.

Also selected is a process for trapping and removing cholesterol from dairy foods, particularly milk. CTT was asked by its strategic alliance partner, the Korea Technology Transfer Center (KTTC), who has exclusive worldwide rights to this technology, to assist in the commercialization of this exciting technology from a premier university in South Korea. The technology has the advantage of being a much more economical method than other existing methods to remove cholesterol from dairy foods and processed meats. The technology removes the cholesterol but leaves intact the natural components of the food especially those that impart texture and taste that are usually removed in cholesterol-free products. CTT plans to commercialize this technology in the North and South American markets.

Competitive Technologies, Inc. has also signed an agreement with New England Medical Center Hospitals, Inc. (NEMCH), a world-class, academic medical center, to exclusively market and commercialize three U.S. patents assigned to NEMCH. The patents relate to methods for identifying cardiovascular therapeutic agents, vasoprotective agents and cardiovascular agents. The invention allows for more specific screening assays to identify vasoprotective and cardiovascular agents, such as a candidate agent's effect on cell proliferation and/or cell activation, or a candidate agent's effect on the expression of a gene which is responsive to estrogen.

"Each year over 1.5 million Americans suffer heart attacks and approximately 500,000 die of that first attack. The economic impact of cardiovascular disease is enormous. Total direct and indirect costs in 2004 were reported to be over $360 billion," stated Aris Despo, Senior VP Life Sciences for CTT. "We feel this is an excellent opportunity to work with a leading U.S. Medical Center and to market a unique technology that is needed by the pharmaceutical industry that will assist in the valuable identification of much needed therapeutic agents. Our Senior Life Science Executive, Dr. Mitch Griffith, will be very active in presenting these patents to candidates who have an active drug development program."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life and physical sciences, electronics, and nanotechnologies developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit our website at: www.competitivetech.net.

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release, other than historical facts, are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks and uncertainties inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2005, filed with the Securities and Exchange Commission ("SEC") on October 13, 2005, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.